截至月份: 2025年6月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海君實生物醫藥科技股份有限公司 呈交日期: 2025年7月4日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01877 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 219,295,700 | RMB | | 1 | RMB | | 219,295,700 | | 增加 / 減少 (-) | | | 41,000,000 | | | | RMB | | 41,000,000 | | 本月底結存 | | | 260,295,700 | RMB | | 1 | RMB | | 260,29 ...

Group 1 - Junshi Biosciences (01877) saw its stock price increase by over 10%, currently trading at 26.2 HKD with a transaction volume of 4.52 billion HKD [1] - The preclinical research results of JS207, a recombinant humanized PD-1 and VEGF bispecific antibody developed by Junshi, were published in the journal "Frontiers in Immunology," detailing its molecular design, in vitro characteristics, functions, and anti-tumor efficacy [1] - According to Founder Securities, the preclinical data of JS207 demonstrates the potential of second-generation PD-1 antibodies in anti-tumor applications, indicating its business development (BD) potential [1] Group 2 - Reports indicate that AstraZeneca is in discussions with Summit regarding a collaboration on the AK112 drug, with a potential deal value of up to 15 billion USD [2] - PD-(L)1/VEGF bispecific antibodies are expected to be the next-generation cornerstone drugs in the immuno-oncology market, with ongoing combinations with ADC/TCE likely to expand market opportunities [2] - As of May 2025, only Pfizer and Merck have entered this market segment among multinational corporations, suggesting that other early-stage PD-(L)1/VEGF bispecific antibodies from China may have opportunities for business development abroad as data matures [2]

港股创新药午后持续拉升，荣昌生物(09995.HK)涨超16%，君实生物(01877.HK)物涨超7%，凯莱英 (06821.HK)涨超5%。 ...

Core Insights - The establishment of the Sci-Tech Innovation Board (STAR Market) has enabled 20 innovative biopharmaceutical companies to list under the fifth set of listing standards, reshaping China's biopharmaceutical landscape [1] - The China Securities Regulatory Commission (CSRC) has introduced measures to enhance the STAR Market's support for high-growth, unprofitable tech companies, emphasizing the importance of "hard technology" [1][3] - The fifth set of listing standards allows unprofitable innovative companies to raise funds, breaking traditional capital market constraints and facilitating financing for R&D-focused firms [1][2] Industry Developments - Since its inception, the STAR Market has seen 20 innovative biopharmaceutical companies adopt the fifth set of listing standards, with significant fundraising efforts directed towards advanced technologies such as antibody drugs and ADCs [1] - In 2024, these 20 companies collectively achieved revenue of 14.21 billion yuan, a year-on-year increase of 44.17%, with several companies projected to exceed 1 billion yuan in revenue soon [1] - Companies like Dizhe Pharmaceutical have reported substantial revenue growth, with a 294.24% increase to 360 million yuan, driven by innovative drug development [2] Company Performance - Companies such as Junshi Biosciences have successfully raised over 8 billion yuan through the STAR Market, significantly advancing their clinical projects and R&D initiatives [2][3] - Ailis, which listed under the fifth set of standards, achieved commercialization of its core product within 2 years and 5 months, demonstrating the effectiveness of the STAR Market in supporting innovative firms [3] - ShenZhou Cell has transitioned from having no products or revenue at the time of listing to achieving 2.51 billion yuan in revenue, marking a successful turnaround [5] Innovation Ecosystem - The STAR Market has fostered an innovation-driven ecosystem, enhancing the flow of resources and increasing recognition of innovative technologies within the capital market [3][4] - Companies are increasingly focusing their resources on R&D, maintaining high levels of investment intensity, and establishing a virtuous cycle of research and development [6] - The introduction of the STAR Market has led to a fundamental shift in the development logic of listed companies, prioritizing quality over scale and fostering collaborative ecosystems [6]

Core Viewpoint - Junshi Bioscience has reported significant growth in its core product, Toripalimab, with a domestic sales revenue of 1.501 billion yuan in 2024, representing a year-on-year increase of approximately 66% [1][2]. Group 1: Sales Performance - The domestic revenue for Toripalimab in the first quarter of 2025 was approximately 447 million yuan, showing a year-on-year growth of about 45.72% [1][2]. - Toripalimab has received approval for 12 indications in mainland China, with 10 of these included in the national medical insurance catalog, enhancing its market accessibility [2][3]. Group 2: R&D Pipeline - The company has expanded its innovative research and development to cover five major therapeutic areas, including oncology, autoimmune diseases, chronic metabolic diseases, neurological diseases, and infectious diseases [3][4]. - Currently, the company has four commercialized drugs and nearly 30 drugs in clinical trials, with over 20 drugs in preclinical development [3][4]. Group 3: Clinical Trials and Internationalization - The PD-1/VEGF bispecific antibody is in Phase II clinical trials, while the anti-BTLA monoclonal antibody combined with Toripalimab is undergoing Phase III clinical research with over 300 patients enrolled [2][5]. - The company aims to achieve globalization through organic growth and strategic partnerships, enhancing its overseas clinical team and pursuing international multi-center clinical trials [5][6].

证券代码：688180 证券简称：君实生物 公告编号：临 2025-037 上海君实生物医药科技股份有限公司 2018 年股权激励方案第三个行权期 行权限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 1,845,200股。 本次股票上市流通总数为1,845,200股。占公司总股本比例为 0.18%，限售期为 自行权之日起三年。 本次股票上市流通日期为2025 年 7 月 7 日。 一、本次上市流通的限售股类型 本次上市流通的限售股为上海君实生物医药科技股份有限公司（以下简称 "公司"）2018 年股权激励方案第三个行权期行权形成，本次上市流通的限售股 股份数量为 1,845,200 股，占截至本公告披露日公司总股本的 0.18%，限售期为自 行权之日起三年，涉及限售股股东 187 名。该部分限售股将于 2025 年 7 月 7 日起 上市流通。 二、本次上市流通的限售股形成后至今公司股本数量变化情况 （一）2020 年限制性 ...

Group 1 - The core viewpoint of the news is that Junshi Biosciences has experienced a decline in stock price, with a cumulative drop of 4.41% over three consecutive days, currently trading at 33.81 CNY per share [1] - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 84.18% of its revenue coming from drug sales [1] - The company has a total market capitalization of 34.712 billion CNY and reported a trading volume of 270 million CNY with a turnover rate of 1.04% [1] Group 2 - According to data, the ICBC Credit Suisse Fund has a significant holding in Junshi Biosciences, with the Kexin Medical ETF (588860) reducing its stake by 242,800 shares, now holding 580,000 shares, which represents 4.15% of the fund's net value [2] - The Kexin Medical ETF has experienced a year-to-date return of 23.12% and ranks 168 out of 4241 in its category since its inception [2] - The fund manager, Shi Baojiao, has been in position for 3 years and 210 days, with the best fund return during this period being 35.42% [2]

Core Viewpoint - The rise of DeepSeek has initiated a "revaluation of Chinese assets," extending beyond the tech sector to new consumption and innovative pharmaceuticals, which are leading the Hong Kong stock market this year [1]. Group 1: Investment Opportunities - International funds' allocation to China remains at historical lows, but there is a growing willingness among global investors to increase their exposure to Chinese assets [1]. - The consensus among industry experts is that both US and Chinese stock markets present investment opportunities this year, with Hong Kong stocks potentially outperforming A-shares [3]. - The MSCI China Index currently has a PE ratio of 11 and a PB ratio of 1.4, indicating that Hong Kong stocks are undervalued compared to the S&P 500 and Nasdaq [4]. Group 2: New Consumption Trends - The consumer sector in Hong Kong has gained more attention than the internet sector this year, with companies like Pop Mart, Mixue Group, and Laoputang being highlighted as key players [6]. - The rise of "self-consumption" reflects a shift in consumer preferences towards quality and high-end experiences, suggesting that companies targeting younger and lower-tier city consumers may have greater opportunities [6][8]. - High valuations in the consumer sector are driven by innovation and the ability to create new IP, rather than merely competing on price [6]. Group 3: Innovative Pharmaceuticals - The Chinese pharmaceutical industry is experiencing a resurgence after three years of stagnation, with global pharmaceutical companies seeking assets in key therapeutic areas [10]. - The Hong Kong healthcare sector has risen by 54% this year, with the Chinese biotech index up 68.6%, significantly outperforming the MSCI China Index [10]. - The trend of "licensing out" innovative drugs is expected to continue, driven by high-value overseas orders and improved geopolitical conditions [11][12].

Group 1 - International capital allocation to China remains at historical lows, but there is a growing willingness among global investors to increase exposure to Chinese assets, particularly in innovative sectors like AI, new consumption, and innovative pharmaceuticals [1][2] - The consensus among industry experts is that both US and Chinese stock markets present investment opportunities this year, with Hong Kong stocks potentially outperforming A-shares [2][3] - The current valuation of the MSCI China Index is at a PE of 11 and PB of 1.4, indicating that Hong Kong stocks are undervalued compared to the high valuations of US stocks, which are reliant on AI narratives [3] Group 2 - The consumer sector in Hong Kong has gained significant attention, surpassing the internet sector in popularity, with companies like Pop Mart and Miko Group being highlighted as key players [4][5] - The growth potential of new consumption in China is linked to the ability to create new IP and resonate with consumers, as well as the capacity to expand internationally [5] - The Chinese pharmaceutical industry is experiencing a resurgence, with significant interest from global pharmaceutical companies seeking assets in key therapeutic areas, leading to a 54% increase in the Hong Kong healthcare sector this year [6][7] Group 3 - The "outbound licensing" theme in innovative pharmaceuticals is gaining traction, driven by high-value overseas licensing deals and increasing recognition of Chinese biotech firms by multinational companies [7][8] - Recent financing activities in the biotech sector, such as the significant capital raises by companies like Hengrui Medicine and Junshi Biosciences, indicate a robust investment environment [7] - The potential for Chinese pharmaceutical companies to enhance their global commercialization capabilities through strategic partnerships is seen as a key growth driver, although challenges remain in terms of innovation and execution [8]

Core Viewpoint - Junshi Biosciences has raised approximately HKD 1.026 billion through a discounted placement of H-shares, reflecting significant cash flow pressures and concerns regarding the sustainability of its financing and R&D model [2][4]. Financing and Capital Structure - The recent placement at HKD 25.35 per share represents an 11.52% discount, marking the largest discount financing in the Hong Kong biopharmaceutical sector this year [2]. - This is the third large-scale financing for Junshi Biosciences in four years, with total fundraising since 2021 reaching approximately RMB 7 billion [3]. - The company has accumulated losses exceeding RMB 10.9 billion since its establishment in 2012, with R&D expenditures totaling RMB 11.419 billion, indicating a heavy reliance on external capital [4]. Financial Performance and Ratios - Junshi's asset-liability ratio increased from 24.64% in 2021 to 47.98% in Q1 2025, indicating rising financial pressure [5][6]. - The company's liquidity ratios have declined significantly, with the current ratio dropping to 1.40 and the quick ratio to 1.20 in Q1 2025, both below industry averages [6][8]. - Cash reserves have decreased from a peak of RMB 6.031 billion at the end of 2022 to RMB 2.522 billion by Q1 2025, a reduction of over 58% [5]. Revenue and Product Dependency - Junshi's revenue heavily relies on its core product, Toripalimab (Tuoyi®), which accounted for over 88% of total revenue in Q1 2025, despite the company still facing losses [9][10]. - The company reported a total revenue of RMB 1.948 billion in 2024, with a net loss of RMB 1.281 billion, although the loss narrowed by 43.90% year-on-year [9]. - International revenue has fluctuated dramatically, dropping from RMB 3.341 billion in 2021 to RMB 0.093 billion in 2024, highlighting instability in the company's revenue structure [10].